Cytek Biosciences Inc
NASDAQ:CTKB

Watchlist Manager
Cytek Biosciences Inc Logo
Cytek Biosciences Inc
NASDAQ:CTKB
Watchlist
Price: 5.93 USD -0.5% Market Closed
Updated: May 29, 2024

Gross Margin
Cytek Biosciences Inc

55.5%
Current
60%
Average
44%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
55.5%
=
Gross Profit
111.4m
/
Revenue
200.8m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
US
Cytek Biosciences Inc
NASDAQ:CTKB
778.3m USD
55%
US
Thermo Fisher Scientific Inc
NYSE:TMO
218.1B USD
40%
US
Danaher Corp
NYSE:DHR
191B USD
58%
US
Agilent Technologies Inc
NYSE:A
43.3B USD
51%
US
IQVIA Holdings Inc
NYSE:IQV
41.3B USD
35%
CH
Lonza Group AG
SIX:LONN
35.7B CHF
36%
KR
Samsung Biologics Co Ltd
KRX:207940
53T KRW
48%
US
Mettler-Toledo International Inc
NYSE:MTD
31.1B USD
59%
IE
ICON PLC
NASDAQ:ICLR
26.5B USD
30%
US
West Pharmaceutical Services Inc
NYSE:WST
23.9B USD
37%
US
Waters Corp
NYSE:WAT
19.7B USD
60%
Cytek Biosciences Inc
NASDAQ:CTKB
Country US
Market Cap 778.3m USD
Gross Margin
55%
Thermo Fisher Scientific Inc
NYSE:TMO
Country US
Market Cap 218.1B USD
Gross Margin
40%
Danaher Corp
NYSE:DHR
Country US
Market Cap 191B USD
Gross Margin
58%
Agilent Technologies Inc
NYSE:A
Country US
Market Cap 43.3B USD
Gross Margin
51%
IQVIA Holdings Inc
NYSE:IQV
Country US
Market Cap 41.3B USD
Gross Margin
35%
Lonza Group AG
SIX:LONN
Country CH
Market Cap 35.7B CHF
Gross Margin
36%
Samsung Biologics Co Ltd
KRX:207940
Country KR
Market Cap 53T KRW
Gross Margin
48%
Mettler-Toledo International Inc
NYSE:MTD
Country US
Market Cap 31.1B USD
Gross Margin
59%
ICON PLC
NASDAQ:ICLR
Country IE
Market Cap 26.5B USD
Gross Margin
30%
West Pharmaceutical Services Inc
NYSE:WST
Country US
Market Cap 23.9B USD
Gross Margin
37%
Waters Corp
NYSE:WAT
Country US
Market Cap 19.7B USD
Gross Margin
60%

Profitability Report

View the profitability report to see the full profitability analysis for Cytek Biosciences Inc.

Full Profitability Report

See Also

Summary
CTKB intrinsic value, competitors valuation, and company profile.
DCF Valuation
CTKB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CTKB stock valuation using valuation multiples.
Wall Street Estimates
CTKB price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CTKB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
55.5%
=
Gross Profit
111.4m
/
Revenue
200.8m
What is the Gross Margin of Cytek Biosciences Inc?

Based on Cytek Biosciences Inc's most recent financial statements, the company has Gross Margin of 55.5%.

ALPHA SPREAD
Join more than 141,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.